Composition for treating radiation-induced intestinal injury and application thereof
Through the compositions Bermatine saponin B4, fermentine, berberine, quinatosin, quinatosin, quinatosin and quinatosin, the treatment problems of radiation enteropathy are solved and the treatment of radiation enteropathy is achieved. The effect of significantly reducing intestinal damage and improving antioxidant capacity provides a safe and efficient treatment plan.
Patent Information
- Application Number
- CN202410900993.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-05
AI Technical Summary
At present, there is a lack of effective drugs for treating radiation intestinal diseases, which has led to a serious reduction in the quality of life of patients with this disease and complex treatment methods, which is difficult to effectively solve the problem of the existing technology.
A composition, including saponin B4, fermentine, berberine, quinatosin, quinatosin and quinatosin, regulate NF-κB, Caspase 9/3 and NRF2 through the action of multiple components and multiple targets. Pathway, alleviate intestinal inflammatory response, protect intestinal barrier and antioxidant capacity.
This composition significantly reduces radiation intestinal damage, improves the antioxidant ability of intestinal tissue, inhibits intestinal inflammatory response, protects intestinal barriers, reduces intestinal tissue damage, and has no toxic side effects and is highly safe. It is suitable for the treatment of radiation intestinal sick.
Smart Images

Figure BDA0004930464500000071
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a composition for treating radiation-induced intestinal injury and application thereof. Background Art
[0002] At present, ionizing radiation is widely used in many fields such as medicine, military, energy and agriculture. While it benefits human life, it is also accompanied by potential safety hazards. Radiation enteropathy is an intestinal disease caused by long-term or high-dose exposure to radiation. This disease usually occurs after receiving radiation treatment or accidental radiation accidents. The main symptoms include adverse reactions such as abdominal pain, diarrhea, blood in the stool and tenesmus, which may even endanger the patient's life and seriously reduce the patient's quality of life. The mechanism of radiation enteropathy is complex and there is currently no effective treatment. Therefore, the development of a drug to treat radiation enteropathy is imminent. Summary of the invention
[0003] In order to solve the above technical problems, the purpose of the present invention is to provide a composition for treating radiation-induced intestinal damage and its application, so as to solve the problem of lack of effective drugs for treating radiation-induced intestinal disease.
[0004] The technical solution of the present invention to solve the above technical problems is as follows:
[0005] A composition for treating radiation-induced intestinal damage comprises the following components: scutellaria saponin B4, phellodendron pine, berberine, aesculetin, aesculetin A and aesculetin E.
[0006] The beneficial effects of the present invention are as follows: the present invention adopts a combination of multiple drugs, and through the effects of multiple components and multiple targets, it has achieved good clinical effects for the long course and complex pathogenesis of radiation-induced intestinal injury. The composition has no toxic side effects and good safety, can significantly reduce radiation-induced intestinal injury, improve the antioxidant capacity of intestinal tissue, inhibit radiation-induced intestinal inflammatory response, and can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect the intestinal barrier, and protect intestinal oxidative damage by regulating the NF-κB, Caspase 9 / 3 and NRF2 pathways, thereby multiple components and multiple pathways work together to treat radiation-induced enteropathy.
[0007] Furthermore, the molar ratio of scutellaria saponin B4, phellodendronine, berberine, quercetin, aesculetin and aesculetin is (1-100): (1-150): (1-50): (1-20): (1-60): (1-60).
[0008] Furthermore, the molar ratio of scutellaria saponin B4, phellodendronine, berberine, quercetin, aesculetin and aesculetin is ((10-30):(5-20):(5-20):(1-5):(20-40):(1-10).
[0009] Furthermore, the molar ratio of scutellaria saponin B4, phellodendronine, berberine, quercetin, quercetin and quercetin is 15:10:8:2:30:4.
[0010] Application of the composition for treating radiation-induced intestinal damage in the preparation of drugs for treating radiation-induced intestinal disease.
[0011] Further, radiation enteropathy includes acute radiation enteropathy, chronic radiation enteropathy, ulcerative colitis and intestinal obstruction.
[0012] A medicine for treating radiation enteropathy, the active ingredient of which comprises the above-mentioned composition for treating radiation enteropathy.
[0013] Furthermore, the dosage form of the drug is injection, powder, pill, microcapsule, soft capsule, film, ointment, tincture, granule or aerosol.
[0014] The present invention has the following beneficial effects:
[0015] Radiation-induced intestinal injury has the characteristics of long course and complex pathogenesis. The present invention adopts a combination of multiple drugs and achieves good clinical effects through the effects of multiple components and multiple targets. The present invention proves through experiments that the composition has no toxic side effects and has good safety. It can significantly reduce intestinal mucosal atrophy and shedding of intestinal villi, reduce the Chiu's score of intestinal tissue damage, increase the length of intestinal villi and the number of crypts, improve the antioxidant capacity of intestinal tissue, inhibit the intestinal inflammatory response caused by radiation, and can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect the intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathways, thereby playing a role in the treatment of radiation-induced enteropathy through multiple components and multiple pathways. DETAILED DESCRIPTION
[0016] The principles and features of the present invention are described below in conjunction with the examples, which are only used to explain the present invention and are not intended to limit the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to conventional conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.
[0017] Embodiment 1:
[0018] A composition for treating radiation-induced intestinal damage, comprising the following components:
[0019] scutellariae saponin B4, phellodendronine, berberine, aesculetin, aesculetin, and aesculetin;
[0020] Among them, the molar ratio of scutellaria saponin B4, phellodendron pine, berberine, quercetin, quercetin A and quercetin E is 15:10:8:2:30:4.
[0021] Embodiment 2:
[0022] A composition for treating radiation-induced intestinal damage, comprising the following components:
[0023] scutellariae saponin B4, phellodendronine, berberine, aesculetin, aesculetin, and aesculetin;
[0024] Among them, the molar ratio of scutellaria saponin B4, phellodendron pine, berberine, quercetin, quercetin A and quercetin E is 1:1:1:1:1:1:1.
[0025] Embodiment 3:
[0026] A composition for treating radiation-induced intestinal damage, comprising the following components:
[0027] scutellariae saponin B4, phellodendronine, berberine, aesculetin, aesculetin, and aesculetin;
[0028] Among them, the molar ratio of scutellaria saponin B4, phellodendron pine, berberine, quercetin, quercetin and quercetin is 100:150:50:20:60:60.
[0029] Test Example 1: Intestinal Pathological Damage Evaluation Experiment
[0030] The composition for treating radiation-induced intestinal injury was administered orally to perform an intestinal pathological injury evaluation experiment.
[0031] The experimental method is:
[0032] Adult healthy male C57BL / 6J mice (7-8 weeks old, weighing 18-20g) were adapted for one week. Before irradiation, each mouse received an abdominal injection of 0.2mL sodium pentobarbital (mass concentration of 0.3%) to ensure its anesthesia during irradiation. Using a medical linear accelerator (CLINAC 23EX-SN297) in X-ray 6MV mode, with a source-skin distance of 100cm and a dose rate of 400MU / min, mice were irradiated with 10Gy at one time to establish a mouse radiation enteropathy model. C57BL / 6J male mice were randomly divided into 6 groups, each containing 6 mice. They were normal group, model group, low-dose, medium-dose and high-dose groups of the combination. The high-dose group of the combination: 30 μM / kg of scutellariae saponin B4 + 20 μM / kg of phellodendronine + 16 μM / kg of berberine + 4 μM / kg of quercetin + 60 μM / kg of quercetin + 8 μM / kg of quercetin. The medium and low-dose groups were diluted twice. After the model was established, the rats were killed and the samples were collected after continuous gavage for 7 days, and then H&E staining was performed. Chiu's score was used to evaluate the damage of intestinal tissue, and GraphPadPrism8.4.0 software was used to analyze and statistically analyze the data.
[0033] The experimental results are shown in Table 1. ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group; * P<0.05 compared with the model group.
[0034] Table 1 Statistics of Chiu's score, villus length and crypt number in different dose groups of the composition
[0035] Grouping Chiu's Rating Villus length (μmol / L) Crypt number Normal group 0.50±0.54 397.66±55.48 29.83±2.92 Model Group <![CDATA[4.20±0.83 ## ]]> <![CDATA[198.00±18.13 ## ]]> <![CDATA[13.00±1.58 ## ]]> Combination low dose group 3.00±0.70 <![CDATA[253.50±14.37 * ]]> 16.20±2.58 Dosage group in the composition <![CDATA[2.33±0.51 ** ]]> <![CDATA[284.50±27.86 ** ]]> <![CDATA[21.33±1.63 ** ]]> Combination high dose group <![CDATA[2.00±0.70 ** ]]> <![CDATA[376.66±15.38 ** ]]> <![CDATA[25.16±1.47 ** ]]>
[0036] The experimental results showed that the composition can significantly reduce intestinal mucosal atrophy, intestinal villus shedding, reduce the Chiu's score of intestinal tissue damage, and increase intestinal villus length and crypt number after treatment. The results showed that the composition can effectively protect intestinal pathological damage and reduce intestinal bleeding.
[0037] Test Example 2: Anti-inflammatory and Antioxidant Capacity Evaluation Experiment
[0038] On the basis of Experimental Example 1, intestinal tissue samples were taken from each group of mice and tested according to the operating instructions of the ELISA kit, SOD kit and MDA kit to detect changes in the content of antioxidant enzymes (SOD), malondialdehyde (MDA) and inflammatory factors (IL-6, IL-10, IL-1β and TNF-α).
[0039] The experimental results are shown in Table 2 and Table 3. Among them, ## P<0.01 compared with the normal group; **P<0.01 compared with the model group; * P<0.05 compared with the model group.
[0040] Table 2 Antioxidant capacity of different doses of the composition
[0041] Grouping SOD MDA Normal group 132.40±4.07 8.26±1.00 Model Group <![CDATA[86.90±4.23 ## ]]> <![CDATA[19.69±2.31 ## ]]> Combination low dose group <![CDATA[97.89±4.92 ** ]]> 17.34±2.02 Dosage group in the composition <![CDATA[105.50±4.69 ** ]]> <![CDATA[13.74±1.53 ** ]]> Combination high dose group <![CDATA[112.20±4.48 ** ]]> <![CDATA[11.16±1.46 ** ]]>
[0042] Table 3 Anti-inflammatory ability of different doses of the composition
[0043] Grouping TNF-α IL-1β IL-6 IL-10 Normal group 58.72±1.52 14.82±1.47 52.71±1.46 87.48±1.94 Model Group <![CDATA[76.90±1.51 ## ]]> <![CDATA[34.59±0.94 ## ]]> <![CDATA[96.80±1.40 ## ]]> <![CDATA[57.93±1.67 ## ]]> Combination low dose group <![CDATA[64.25±1.02 ** ]]> <![CDATA[27.81±0.76 ** ]]> <![CDATA[87.72±1.87 ** ]]> <![CDATA[61.88±0.93 * ]]> Dosage group in the composition <![CDATA[61.55±0.88 ** ]]> <![CDATA[24.58±0.86 ** ]]> <![CDATA[78.92±1.30 ** ]]> <![CDATA[65.45±1.29 ** ]]> Combination high dose group <![CDATA[59.40±1.07 ** ]]> <![CDATA[19.62±1.11 ** ]]> <![CDATA[71.24±1.79 ** ]]> <![CDATA[75.31±1.34 ** ]]>
[0044] The experimental results showed that compared with the normal group, the activity of the intestinal antioxidant enzyme SOD in the model group mice was significantly reduced, the level of lipid peroxide MDA was significantly increased, the levels of proinflammatory factors TNF-α, IL-1β, and IL-6 were increased, and the level of anti-inflammatory factor IL-10 was reduced. The composition dose-dependently inhibited the levels of proinflammatory factors TNF-α, IL-1β, and IL-6, promoted the secretion of anti-inflammatory factor IL-10, and alleviated intestinal inflammation. The composition dose-dependently increased SOD activity and reduced the content of MDA, improving the antioxidant capacity of the intestine. The results show that the composition can improve the antioxidant capacity of the intestinal tissue of irradiated mice and inhibit the intestinal inflammatory response caused by radiation.
[0045] Experimental Example 3: Effect of the composition on the expression of NF-κB pathway proteins
[0046] The prepared composition was used for experiments to evaluate the effect of the composition on the expression of NF-κB pathway proteins. The cells used in the experiment were normal human intestinal epithelial cells HIEC-6 (ATCC cell bank, USA), HY-18738 inhibitor was used as a control, and conventional Western blot method was used for testing.
[0047] The implementation method is: a cell radiation damage model was constructed with a 4Gy X-ray dose. The cell experiments were divided into normal group, model group, high-dose combination group, inhibitor group, high-dose combination + inhibitor group. The high-dose component group: scutellaria saponin B4 2.3μmol / L + phellodendron pine 1.53μmol / L + berberine 1.23μmol / L + quercetin 0.31μmol / L + quercetin A 4.60μmol / L + quercetin E 0.61μmol / L; inhibitor group: 100μmol / L. After 24 hours of drug intervention, samples were collected for detection.
[0048] The experimental results are shown in Table 4. Among them, ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group.
[0049] Table 4 Effects of the composition on the expression of NF-κB pathway proteins
[0050] Grouping pP-65 / P-65 Normal group 0.18±0.02 Model Group <![CDATA[0.79±0.05 ## ]]> Combination high dose group <![CDATA[0.39±0.04 ** ]]> Inhibitor group <![CDATA[0.32±0.05 ** ]]> Combination high dose + inhibitor group <![CDATA[0.40±0.04 ** ]]>
[0051] The experimental results showed that the expression of p-P65 protein in the model group was significantly increased, and the expression of p-P65 protein was significantly decreased after treatment with the composition, indicating that the composition can exert an anti-inflammatory effect by inhibiting the NF-κB pathway.
[0052] Experimental Example 4: Effect of the Composition on the Expression of Caspase 9 / 3 Pathway Proteins
[0053] The prepared composition was used for experiments to evaluate the effect of the composition on the expression of Caspase 9 / 3 pathway proteins. The cells used in the experiment were normal human intestinal epithelial cells HIEC-6 (ATCC cell bank, USA), HY-12305 inhibitor was used as a control, and the conventional Western blot method was used for testing.
[0054] The implementation method is: a cell radiation damage model was constructed with a 4Gy X-ray dose. The cell experiments were divided into normal group, model group, high-dose combination group, inhibitor group, high-dose combination + inhibitor group. The high-dose component group: scutellaria saponin B4 2.3μmol / L + phellodendron pine 1.53μmol / L + berberine 1.23μmol / L + quercetin 0.31μmol / L + quercetin A 4.60μmol / L + quercetin E 0.61μmol / L; inhibitor group: 400nM. After 24 hours of drug intervention in each group, samples were collected for detection.
[0055] The experimental results are shown in Table 5. Among them, ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group.
[0056] Table 5 Effects of the composition on the expression of Caspase 9 / 3 pathway proteins
[0057]
[0058] The experimental results showed that the expression of Cle-Caspase 9 / 3 protein in the model group was significantly increased, and the expression of Cle-Caspase 9 / 3 protein was significantly decreased after treatment with the composition, indicating that the composition can exert an anti-apoptotic effect by inhibiting the Caspase9 / 3 pathway and protect the intestinal barrier.
[0059] Experimental Example 5: Effect of the Composition on the Expression of NRF2 Pathway Proteins
[0060] The composition prepared in Example 1 was used for experiments to evaluate the effect of the composition on the expression of NRF 2 pathway proteins. The cells used in the experiment were normal human intestinal epithelial cells HIEC-6 (ATCC cell bank, USA), and the HY-112675 inhibitor was used as a control. The conventional Western blot method was used for testing.
[0061] The implementation method is: a cell radiation damage model was constructed with a 4Gy X-ray dose. The cell experiments were divided into normal group, model group, high-dose combination group, agonist group, high-dose combination + agonist group. The high-dose component group: scutellaria saponin B4 2.3μmol / L + phellodendron 1.53μmol / L + berberine 1.23μmol / L + quercetin 0.31μmol / L + quercetin A 4.60μmol / L + quercetin E 0.61μmol / L; the agonist group: 30μmol / L. After 24 hours of drug intervention, samples were collected for detection.
[0062] The experimental results are shown in Table 6. Among them, ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group.
[0063] Table 6 Effects of the composition on the expression of NRF2 pathway proteins
[0064] Grouping NRF2 / GAPDH Normal group 0.81±0.03 Model Group <![CDATA[0.37±0.03 ## ]]> Combination high dose group <![CDATA[1.02±0.10 ** ]]> Agonist group <![CDATA[0.93±0.06 ** ]]> Combination high dose + agonist group <![CDATA[0.98±0.07 ** ]]>
[0065] The experimental results showed that the expression of NRF2 protein in the model group decreased significantly, and the expression of NRF2 protein increased significantly after treatment with the composition, indicating that the composition can exert an antioxidant effect and protect the intestinal barrier by inhibiting the NRF2 pathway.
[0066] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A composition for treating radiation-induced intestinal damage, characterized in that: The invention comprises the following components: scutellaria saponin B4, phellodendron pine, berberine, quercetin, quercetin A and quercetin Et.
2. The composition for treating radiation-induced intestinal damage according to claim 1, characterized in that: The molar ratio of scutellaria saponin B4, phellodendronine, berberine, aesculetin, aesculetin and aesculetin is (1-100): (1-150): (1-50): (1-20): (1-60): (1-60).
3. The composition for treating radiation-induced intestinal damage according to claim 2, characterized in that: The molar ratio of scutellaria saponin B4, phellodendronine, berberine, quercetin, aesculetin and aesculetin is (10-30): (5-20): (5-20): (1-5): (20-40): (1-10).
4. The composition for treating radiation-induced intestinal damage according to claim 3, characterized in that: The molar ratio of scutellaria saponin B4, phellodendron pine, berberine, quercetin, quercetin A and quercetin E is 15:10:8:2:30:
4.
5. Use of the composition for treating radiation-induced intestinal damage according to any one of claims 1 to 4 in the preparation of a drug for treating radiation-induced enteropathy.
6. The use according to claim 4, characterized in that: The radiation enteropathy includes acute radiation enteropathy, chronic radiation enteropathy, ulcerative colitis and intestinal obstruction.
7. A drug for treating radiation enteropathy, characterized in that: The active ingredient comprises the composition for treating radiation-induced intestinal damage according to any one of claims 1 to 4.
8. The drug for treating radiation enteropathy according to claim 7, characterized in that: The dosage form of the medicine is injection, powder, pill, microcapsule, soft capsule, film, ointment, tincture, granule or aerosol.
Citation Information
Patent Citations
Application of pulsatilla saponin B4 in preparing anti-inflammatory bowel disease drug
CN109549944A
Method for determining content of multi-component chemical components in Chinese pulsatilla root decoction
CN113884587A
Application of pulsatilla saponin b4 in preparation of medicine for preventing or treating non-alcoholic fatty liver diseases
WO2023051025A1
